Work

15P Topical strategy to prevent skin toxicities from bispecific-EGFR inhibitors by blocking drug-receptor interactions in skin

Year: 2025

Type: article

Abstract: Epidermal growth factor receptor inhibitors (EGFRi) commonly cause severe skin toxicity, particularly papulopustular eruptions. These lesions often lead patients to discontinue or reduce treatment. Current treatments mainly address symptoms, failing to prevent the initial trigger of toxicity and offering limited benefit . In our previous work, we developed a compound and method to prevent “on-target” skin toxicity by topically blocking the drug-receptor interactions of cetuximab and panitumumab at the site of toxicity.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2025.104171

Authors: S. Merims, L. Aharonov, Y. Hazut, L. Weinstein, O. Benny

Institutions: Hadassah Medical Center, Hebrew University of Jerusalem

Language: English

Topic: Chemotherapy-related skin toxicity

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,910